GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » EV-to-FCF

iX Biopharma (SGX:42C) EV-to-FCF : -4.15 (As of May. 10, 2024)


View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, iX Biopharma's Enterprise Value is S$29.88 Mil. iX Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was S$-7.20 Mil. Therefore, iX Biopharma's EV-to-FCF for today is -4.15.

The historical rank and industry rank for iX Biopharma's EV-to-FCF or its related term are showing as below:

SGX:42C' s EV-to-FCF Range Over the Past 10 Years
Min: -34.17   Med: -14.97   Max: 42.58
Current: -5

During the past 10 years, the highest EV-to-FCF of iX Biopharma was 42.58. The lowest was -34.17. And the median was -14.97.

SGX:42C's EV-to-FCF is ranked worse than
100% of 509 companies
in the Drug Manufacturers industry
Industry Median: 23.25 vs SGX:42C: -5.00

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-10), iX Biopharma's stock price is S$0.039. iX Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was S$-0.013. Therefore, iX Biopharma's PE Ratio for today is At Loss.


iX Biopharma EV-to-FCF Historical Data

The historical data trend for iX Biopharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma EV-to-FCF Chart

iX Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.77 -17.23 -18.57 38.78 -8.09

iX Biopharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 38.78 - -8.09 -

Competitive Comparison of iX Biopharma's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iX Biopharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where iX Biopharma's EV-to-FCF falls into.



iX Biopharma EV-to-FCF Calculation

iX Biopharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=29.883/-7.201
=-4.15

iX Biopharma's current Enterprise Value is S$29.88 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. iX Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was S$-7.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iX Biopharma  (SGX:42C) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

iX Biopharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.039/-0.013
=At Loss

iX Biopharma's share price for today is S$0.039.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. iX Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was S$-0.013.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


iX Biopharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of iX Biopharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


iX Biopharma (SGX:42C) Business Description

Traded in Other Exchanges
N/A
Address
1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma (SGX:42C) Headlines

No Headlines